THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 261 participants.
Also called NCT06559891
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 261 participants
- Registry
-
NCT06559891
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, France, Germany, Greece, Italy
- Registry status
- Recruiting
Technical summary
Registry record NCT06559891. Randomized; triple masking; primary purpose treatment. Start 2024-10-03 (actual); primary completion 2027-03-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
- Acronym
- THRIVE
- Condition
- Hypertension
- Intervention (Device)
- TIVUS™ Renal Denervation System
- Intervention (Other)
- Sham
- Lead sponsor
- SoniVie Inc.
- Collaborator
- NAMSA
- Collaborator
- European Cardiovascular Research Center
- Collaborator
- IQVIA Pty Ltd
Record details
- Record id
cardio:ct-nct06559891- Content hash
4f19739b445d821b7af4eb3a1ad8fd88a2167e54c5dcd00802c4aa28df37d3ec